{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Rationale', 'Amendment number:', 'Amendment 3', 'Rationale/background for changes:', 'The protocol has been amended to implement the following changes:', 'Removal of all STGG (Skim Milk-Tryptone-Glucose-Glycerol) wording', 'throughout the protocol. STGG product not being available, it has been decided to', 'replace it with cryobeads for storage of bacterial isolates. PCR testing on samples', 'stored in cryobeads was shown to be as efficient as for samples stored in STGG.', 'Besides, this decision has been taken for alignment with other COPD studies,', 'where STGG solutions are no longer used.', 'Clarification of technique used for target identification. For the primary endpoint,', 'various viral pathogens will be identified but not quantified. Along this line, the', 'wording \"and by HRV quantitative RT-PCR\" has been removed from primary', 'endpoint to avoid confusion as HRV viral load data will be reported as part of the', 'tertiary endpoints.', 'Clarification in exclusion criteria section (4.3). Administration of antibiotics', 'before study entry, where study entry is meant to be Visit 1.', 'Clarification in study procedure section (6.3) and in the section for recording', 'current medication (6.4.2.10) during scheduled visits, where it has been specified', 'that recording of any current medication is applicable for any disease not only', 'COPD-related. Moreover, a footnote referring to Table 10 \"Reporting period for', 'SAE and AEs leading to withdrawal\" has been added for further clarification, both', 'in Table 4 and 5.', 'Addition of a section (actual 6.4.2.6) for Pregnancy test for Visit 1, Visit 2 and', 'Visit 3. A Pregnancy test section for Screening Visit was included during Protocol', 'Amendment 1: to be consistent, same wording has been included for the', 'subsequent visits.', 'Clarification of reporting of severe AECOPDs. Two sentences have been added in', 'sections 7.1.1 and 7.2.2.1 for making clear that severe AECOPD events are not to', 'be reported as SAE as they are meant as disease-related outcomes.', 'Rewording in the table concerning reporting period for SAE and AEs leading to', 'withdrawal for better clarification (Table 10).', 'Addition of a new outsourced laboratory (DDL).', 'To correct some typographical errors.', '19-OCT-2018', '4', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Investigator Agreement', 'I agree:', 'To conduct the study in compliance with this protocol, any mutually agreed future', 'protocol amendments or protocol administrative changes, with the terms of the study', 'agreement and with any other study conduct procedures and/or study conduct', 'documents provided by GlaxoSmithKline (GSK) Biologicals.', 'To assume responsibility for the proper conduct of the study at this site.', \"That I am aware of, and will comply with, 'Good Clinical Practice' (GCP) or other\", 'applicable guidelines and all applicable regulatory requirements.', 'To ensure that all persons assisting me with the study are adequately informed about', 'study-related duties and functions as described in the protocol.', 'To acquire the reference ranges for laboratory tests performed locally and, if required', \"by local regulations, obtain the laboratory's current certification or Quality\", 'Assurance procedure manual.', 'To ensure that no samples (including serum samples) are retained onsite or elsewhere', 'without the approval of GSK Biologicals and the express written informed consent of', \"the subject and/or the subject's legally acceptable representative.\", 'To perform no other biological assays on the samples except those described in the', 'protocol or its amendment(s).', 'To co-operate with a representative of GSK Biologicals in the monitoring process of', 'the study and in resolution of queries about the data.', 'That I have been informed that certain regulatory authorities require the sponsor to', \"obtain and supply, as necessary, details about the investigator's ownership interest in\", 'the sponsor, and more generally about his/her financial ties with the sponsor. GSK', 'Biologicals will use and disclose the information solely for the purpose of complying', 'with regulatory requirements.', 'Hence I:', 'Agree to supply GSK Biologicals with any necessary information regarding', 'ownership interest and financial ties (including those of my spouse and dependent', 'children).', 'Agree to promptly update this information if any relevant changes occur during the', 'course of the study and for one year following completion of the study.', 'Agree that GSK Biologicals may disclose any information it has about such', 'ownership interests and financial ties to regulatory authorities.', 'Agree to provide GSK Biologicals with an updated Curriculum Vitae and other', 'documents required by regulatory agencies for this study.', '19-OCT-2018', '5', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}